This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Y-mAbs Therapeutics Yönetim
Yönetim kriter kontrolleri 1/4
Y-mAbs Therapeutics CEO'su Mike Rossi, Nov2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 4.56M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.5% maaş ve 84.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.056% ine doğrudan sahiptir ve bu hisseler $ 216.74K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 7.8 yıldır.
Anahtar bilgiler
Mike Rossi
İcra Kurulu Başkanı
US$4.6m
Toplam tazminat
| CEO maaş yüzdesi | 15.48% |
| CEO görev süresi | 1.8yrs |
| CEO sahipliği | 0.06% |
| Yönetim ortalama görev süresi | 1.3yrs |
| Yönetim Kurulu ortalama görev süresi | 7.8yrs |
Son yönetim güncellemeleri
Recent updates
Seeking Alpha • Aug 06
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 06
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.Analiz Makalesi • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Analiz Makalesi • Apr 29
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
Yeni Anlatı • Mar 31
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Analiz Makalesi • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Seeking Alpha • Jan 24
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 10
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...Analiz Makalesi • Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analiz Makalesi • Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Oct 21
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking AlphaAnaliz Makalesi • Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Seeking Alpha • Aug 12
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analiz Makalesi • Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • May 09
Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...Analiz Makalesi • Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Seeking Alpha • Jan 14
Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$28m |
| Dec 31 2024 | US$5m | US$706k | -US$30m |
| Sep 30 2024 | n/a | n/a | -US$24m |
| Jun 30 2024 | n/a | n/a | -US$25m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$3m | US$110k | -US$21m |
Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 4.56M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.41M ).
Tazminat ve Kazançlar: Mike şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Mike Rossi (54 yo)
1.8yrs
Görev süresi
US$4,557,590
Tazminat
Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$4.56m | 0.056% $ 216.7k | |
| Founder | 10.4yrs | US$2.08m | 0.82% $ 3.2m | |
| Executive VP | 1.3yrs | US$2.75m | 0.13% $ 496.8k | |
| Senior VP & COO | 7.8yrs | Veri yok | 0.028% $ 110.0k | |
| Senior VP & CTO | 9.7yrs | Veri yok | 0.11% $ 443.2k | |
| VP & Head of Investor Relations | no data | Veri yok | Veri yok | |
| Senior VP | less than a year | Veri yok | Veri yok | |
| Chief Development Officer & Chief Medical Officer | 1.3yrs | Veri yok | Veri yok | |
| Senior VP & Head of DANYELZA Business Unit | less than a year | Veri yok | Veri yok | |
| Senior VP & Radiopharmaceutical Business Unit Head | less than a year | Veri yok | Veri yok |
1.3yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş
Deneyimli Yönetim: YMAB 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 1.8yrs | US$4.56m | 0.056% $ 216.7k | |
| Founder | 10.4yrs | US$2.08m | 0.82% $ 3.2m | |
| Independent Chairman of the Board | 7.8yrs | US$262.79k | 0.070% $ 271.5k | |
| Independent Director | 7.8yrs | US$250.29k | 0.013% $ 50.0k | |
| Independent Director | 10yrs | US$227.79k | 0.013% $ 50.0k | |
| Independent Director | 7.8yrs | US$227.79k | 0.013% $ 50.0k | |
| Independent Director | 5.3yrs | US$237.79k | 0.013% $ 50.0k |
7.8yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: YMAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2025/09/15 08:03 |
| Gün Sonu Hisse Fiyatı | 2025/09/15 00:00 |
| Kazançlar | 2025/06/30 |
| Yıllık Kazançlar | 2024/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Y-mAbs Therapeutics, Inc. 8 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |